secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2023-04-04T23:59:59+00:00
Accession:  0001689375-23-000023
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada Therapeutics appoints Dr. Bernhardt Zeiher to Board of Directors
------------------------------------------------------------------------

- Board expanded from 7 to 8; Dr. Zeiher appointed as Class II director and to Nominating and Corporate Governance Committee.
- Dr. Zeiher most recently served as Chief Medical Officer at Astellas Pharma; brings clinical and regulatory expertise.
- Received initial option for 32,000 shares vesting over 3 years; annual director fee of $40,000 plus committee fee.
- Entrada's lead programs include Duchenne muscular dystrophy and myotonic dystrophy type 1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000168937523000023/0001689375-23-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000168937523000023/trda-20230404.htm
  HTML page:      https://secwatch.observer/filing/0001689375-23-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer